|
www.advancedcell.com
Description
Advanced Cell Technology is a biotechnology company focused on applying stem cell technology in the field of regenerative medicine to bring effective, patient-specific therapies to the bedside.
News
-
05/10/11
Advanced Cell Technology to present at World Stem Cell Summit in California -
23/09/11
Advanced Cell Technology gets green light for Europe's first human embryonic stem cell trial -
28/06/11
Advanced Cell and Roslin to collaborate on developing a stem cell bank -
18/06/11
Advanced Cell enrolls first patients in 2 clinical trials for eye disease stem cell treatments -
18/05/11
Advanced Cell Technology announces site for Stargardt's stem cell trial -
05/05/11
Advanced Cell welcomes decision to lift ban on federal embryonic stem cell research funding -
03/05/11
Advanced Cell Technology receives approval for clinical trial location -
28/04/11
Advanced Cell files European clinical trial application for Stargardt's treatment -
01/04/11
Advanced Cell Technology to be issued key Chinese IP patent for stem cell program -
31/03/11
Advanced Cell Technology achieves strongest financial position yet
Recent Sector News
-

Medical Australia completes milestone first animal stem cell treatments in U.K.
The TUTAVet animal stem cell therapy has substantial commercial upside for Medical Australia. Following the completion of the first two procedures in the U.K. the company has generated strong interest from veterinary surgeons keen to trial the technology.
-

Medical Australia secures first mover advantage in Europe with animal stem cell therapy
Mark Donnison, managing director of Medical Australia, told Proactive Investors today the roll out of a new unique regenerative animal stem cell therapy offering in Europe presents the company with three potential revenue streams.
-

Medical Australia boosts FY2012 revenue by A$1.5m with new supply agreements
New supply contracts indicate the strong organic revenue growth Medical Australia is experiencing across the business and with further prospects the company is on a solid growth footing for FY2012 and beyond.
-

Circadian Technologies moves into clinical development phase on approval of IND for cancer drug
The FDA’s approval of Circadian’s Investigational New Drug application for its antibody to treat cancer means the company is now well placed to begin the transition to a clinical development company.
-

Circadian Technologies: Van Leeuwenhoeck places share price target of $1.97
Van Leeuwenhoeck considers Circadian as "gravely undervalued at current share price of $0.50", and based on a sum-of-the-parts valuation, values the company at A$1.97 - around four times the last traded price - highlighting significant upside potential.
-

Circadian Technologies looks to royalties on cancer diagnostic test with Healthscope
Healthscope has paid Circadian an upfront fee, and will pay a royalty on sales of the CUP test. The CUP test will be commercially available early next year, ringing in the transition for Circadian into a clinical development company.
Investors interested in Advanced Cell Technology recently viewed
-
e-Therapeutics plc (AIM: ETX) Systems Biology Drug Discovery -
Inovio Pharmaceuticals (NYSE AMEX: INO) Leadership in the development of next-generation vaccines -
Asterand (LSE: ATD) Leading global supplier of high quality tissue-bas -
Amphion Innovations (LON: AMP) Amphion builds shareholder value in the medical and technology sectors -
iBio (AMEX: IBIO) Development and commercialization of novel plant-made products












